JC07 Rec'd PCT/PTO 19 DEC 2001

FORM PTO-1390 (REV. 9-2001) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371

ATTORNEY'S DOCKET NUMBER: YAM 2 0013

U.S. APPLICATION NO. (If known, see 37 CFR 1.5): 10/018924

INTERNATIONAL APPLICATION NO.	INTERNATIONAL FILING DATE	PRIORITY DATE CLAIMED
PCT/JP00/04166	23 June 2000	23 June 1999

TITLE OF INVENTION: COMPOSITION FOR PROMOTING PASSIVE EXTENSION OF BLADDER SMOOTH MUSCLE

APPLICANT(S) FOR DO/EO/US: YANAGITA, Toshihiko

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. [X] This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. [ ] This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. [X] This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below.
4. [X] The US has been elected by the expiration of 19 months from the priority date (Article 31).
5. [X] A copy of the International Application as filed (35 U.S.C. 371(c)(2))
   a. [ ] is attached hereto (required only if not communicated by the International Bureau).
   b. [X] has been communicated by the International Bureau.
   c. [ ] is not required, as the application was filed in the United States Receiving Office (RO/US).
6. [X] An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).
   a. [X] is attached hereto.
   b. [ ] has been previously submitted under 35 U.S.C. 154(d)(4).
7. [X] Amendments to the claims of the International Aplication under PCT Article 19 (35 U.S.C. 371(c)(3))
   a. [ ] are attached hereto (required only if not communicated by the International Bureau).
   b. [ ] have been communicated by the International Bureau.
   c. [ ] have not been made; however, the time limit for making such amendments has NOT expired.
   d. [X] have not been made and will not be made.
8. [ ] An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371 (c)(3)).
9. [X] An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).
10. [ ] An English lanugage translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

Items 11 to 20 below concern document(s) or information included:

11. [ ] An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
12. [X] An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13. [X] A FIRST preliminary amendment.
14. [ ] A SECOND or SUBSEQUENT preliminary amendment.
15. [ ] A substitute specification.
16. [ ] A change of power of attorney and/or address letter.
17. [X] A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821 - 1.825.
18. [ ] A second copy of the published international application under 35 U.S.C. 154(d)(4).
19. [ ] A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).
20. [X] Other items or information:

Application Data Sheet
Sequence Listing (12 pages)
Verified Statement Under 37 CFR 1.821(f)

Express Mail Label No. EL 852683336 US
Date of Deposit December 19, 2001
I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Laurie A. Boylan
(TYPED OR PRINTED NAME OF PERSON)
LAURIE A. BOYLAN

U.S. APPLICATION NO (if known, see 37 CFR 1.5)	INTERNATIONAL APPLICATION NO	ATTORNEY'S DOCKET NUMBER
10/018924	PCT/JP00/04166	YAM 2 0013

21. ☐ The following fees are submitted:	CALCULATIONS PTO USE ONLY	
BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)):		
Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO **$1040.00**		
International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO **$890.00**		
International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO **$740.00**		
International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4) **$710.00**		
International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4) **$100.00**		
ENTER APPROPRIATE BASIC FEE AMOUNT =	$ 890.00	
Surcharge of **$130.00** for furnishing the oath or declaration later than ☐ 20 ☐ 30 months from the earliest claimed priority date (37 CFR 1.492(e)).	$	

CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE		
Total claims	14 - 20 =	0	x **$18.00**	$	
Independent claims	3 - 3 =	0	x **$84.00**	$	
MULTIPLE DEPENDENT CLAIM(S) (if applicable)			+ **$280.00**	$	
TOTAL OF ABOVE CALCULATIONS =				$	
☐ Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2. +				$	
SUBTOTAL =				$ 890.00	
Processing fee of **$130.00** for furnishing the English translation later than ☐ 20 ☐ 30 months from the earliest claimed priority date (37 CFR 1.492(f)).				$	
TOTAL NATIONAL FEE =				$ 890.00	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). **$40.00** per property +				$ 40.00	
TOTAL FEES ENCLOSED =				$ 930.00	
				Amount to be refunded:	$
				charged:	$

a. ☒ A check in the amount of $ 930.00 to cover the above fees is enclosed.

b. ☐ Please charge my Deposit Account No. _____ in the amount of $ _____ to cover the above fees. A duplicate copy of this sheet is enclosed.

c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 06-0308 A duplicate copy of this sheet is enclosed.

d. ☐ Fees are to be charged to a credit card. **WARNING:** Information on this form may become public. **Credit card information should not be included on this form.** Provide credit card information and authorization on PTO-2038.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137 (a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

Richard M. Klein
FAY, SHARPE, FAGAN, MINNICH & McKEE, LLP
1100 Superior Avenue, Seventh Floor
Cleveland, OH 44114
RKlein@faysharpe.com
(216) 861-5582

Richard M. Klein
SIGNATURE

Richard M. Klein
NAME

33,000
REGISTRATION NUMBER

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of
YANAGITA, Toshihiko

International Application No. PCT/JP00/04166
International Filing Date June 23, 2000

For: COMPOSITION FOR PROMOTING PASSIVE EXTENSION OF BLADDER SMOOTH MUSCLE

Attorney Docket No. YAM 2 0013

Cleveland, Ohio 44114
December 19, 2001

PRELIMINARY AMENDMENT

BOX Patent Application
Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

Prior to the examination of the merits and/or calculation of the fees, kindly amend the above-identified application as follows:

IN THE CLAIMS:

Please amend claims **8, 9, and 10** to read as follows:

8. (Amended) A composition according to claim 1, wherein the C-terminus of the adrenomedullin is amidated.

9. (Amended) A composition according to claim 1, wherein Gly is added to the C-terminus of the adrenomedullin.

10. (Amended) A composition according to claim 1, wherein in the adrenomedullin, Cys in position 16 and Cys in position 21 of SEQ ID NO: 2 in SEQUENCE LISTING are crosslinked.

REMARKS

Entry of this preliminary amendment is requested at the U.S. Patent and Trademark Office's earliest convenience.

Respectfully submitted,

FAY, SHARPE, FAGAN,
MINNICH & McKEE, LLP

By: 

Richard M. Klein
Reg. No. 33,000
1100 Superior Avenue
Seventh Floor
Cleveland, Ohio 44114
Telephone: 216-861-5582
Facsimile: 216-241-1666
E-mail: *rklein@faysharpe.com*

Attachment - Version With Markings to Show Changes Made

lab429a.wpd

VERSION WITH MARKINGS TO SHOW CHANGES MADE

Please amend claims **8, 9 and 10** (i.e. additions are underlined and deletions are bracketed) to read as follows:

IN THE CLAIMS:

8. (Amended) A composition according to [any of claims 1 and 4 to 7] claim 1, wherein the C-terminus of the adrenomedullin is amidated.

9. (Amended) A composition according to [any of claims 1 and 4 to 7] claim 1, wherein Gly is added to the C-terminus of the adrenomedullin.

10. (Amended) A composition according to [any of claims 1 and 4 to 7] claim 1, wherein in the adrenomedullin, Cys in position 16 and Cys in position 21 of SEQ ID NO: 2 in SEQUENCE LISTING are crosslinked.

"EXPRESS MAIL" Mailing Label Number EL852683386US
Date of Deposit: **December 19, 2001**

I hereby certify that this **Verified Statement Under 37 C.F.R. § 1.821(f)** is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Laurie A. Boylan

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF	:	YANAGITA, Toshihiko
FOR	:	**COMPOSITION FOR PROMOTING PASSIVE EXTENSION OF BLADDER SMOOTH MUSCLE**
SERIAL NO.	:	Unknown
FILED	:	Herewith
INTERNATIONAL APPLICATION NO.	:	PCT/JP00/04166
INTERNATIONAL FILING DATE	:	23 JUNE 2000
ATTORNEY DOCKET NO.	:	YAM 2 0013

Cleveland, Ohio 44114-2518
December 19, 2001

VERIFIED STATEMENT UNDER 37 C.F.R. § 1.821(f)

Box Patent Application
Assistant Commissioner for Patents
Washington, DC 20231

Dear Sir:

Herewith is a verified statement declaring that the information recorded on the enclosed diskette is identical to the information written sequence listing.

1. I hereby state that the information recorded in computer readable form is identical to the written sequence listing as required under 37 C.F.R. § 1.821(f).

2. I hereby state that the submission filed in accordance with 37

C.F.R. § 1.821(g), herein does not include new matter or matter which goes beyond the disclosure in the international application.

Respectfully submitted,

FAY, SHARPE, FAGAN
MINNICH & MCKEE, LLP

Date: 12/19/2001

Richard M. Klein
Reg. No. 33,000
1100 Superior Avenue, 7th Floor
Cleveland, Ohio 44114-2516
(216) 861-5582

N:\YAM\20013\LAB0437A.WPD

PCT10

RAW SEQUENCE LISTING DATE: 01/17/2002
PATENT APPLICATION: US/10/018,924 TIME: 07:15:17

Input Set : A:\SO042PCTSEQ.txt
Output Set: N:\CRF3\01172002\J018924.raw

ENTERED

```
      2 <110> APPLICANT: Shionogi & Co., Ltd
      4 <120> TITLE OF INVENTION: Composition for promoting passive extension of bladder
smooth muscle
W--> 5 <130> FILE REFERENCE: SO042PCT
C--> 7 <140> CURRENT APPLICATION NUMBER: US/10/018,924
C--> 8 <141> CURRENT FILING DATE: 2001-12-19
      9 <150> PRIOR APPLICATION NUMBER: JP P1999-177549
     10 <151> PRIOR FILING DATE: 1999-06-23
     12 <160> NUMBER OF SEQ ID NOS: 6
     14 <170> SOFTWARE: PatentIn Ver. 2.0
     16 <210> SEQ ID NO: 1
     17 <211> LENGTH: 1457
     18 <212> TYPE: DNA
     19 <213> ORGANISM: Homo sapiens
     21 <220> FEATURE:
     22 <221> NAME/KEY: CDS
     23 <222> LOCATION: (165)..(719)
     25 <220> FEATURE:
W--> 26 <221> NAME/KEY: mat peptide
     27 <222> LOCATION: (447)..(602)
     29 <400> SEQUENCE: 1
     30 ggcacgagct ggatagaaca gctcaagcct tgccacttcg ggcttctcac tgcagctggg 60
     32 cttggacttc ggagttttgc cattgccagt gggacgtctg agactttctc cttcaagtac 120
     34 ttggcagatc actctcttag cagggtctgc gcttcgcagc cggg atg aag ctg gtt  176
     35                                                 Met Lys Leu Val
     37 tcc gtc gcc ctg atg tac ctg ggt tcg ctc gcc ttc cta ggc gct gac   224
     38 Ser Val Ala Leu Met Tyr Leu Gly Ser Leu Ala Phe Leu Gly Ala Asp
     39 -90                 -85                 -80                 -75
     41 acc gct cgg ttg gat gtc gcg tcg gag ttt cga aag aag tgg aat aag   272
     42 Thr Ala Arg Leu Asp Val Ala Ser Glu Phe Arg Lys Lys Trp Asn Lys
     43                 -70                 -65                 -60
     45 tgg gct ctg agt cgt ggg aag agg gaa ctg cgg atg tcc agc agc tac   320
     46 Trp Ala Leu Ser Arg Gly Lys Arg Glu Leu Arg Met Ser Ser Ser Tyr
     47             -55                 -50                 -45
     49 ccc acc ggg ctc gct gac gtg aag gcc ggg cct gcc cag acc ctt att   368
     50 Pro Thr Gly Leu Ala Asp Val Lys Ala Gly Pro Ala Gln Thr Leu Ile
     51         -40                 -35                 -30
     53 cgg ccc cag gac atg aag ggt gcc tct cga agc ccc gaa gac agc agt   416
     54 Arg Pro Gln Asp Met Lys Gly Ala Ser Arg Ser Pro Glu Asp Ser Ser
     55     -25                 -20                 -15
     57 ccg gat gcc gcc cgc atc cga gtc aag cgc tac cgc cag agc atg aac   464
     58 Pro Asp Ala Ala Arg Ile Arg Val Lys Arg Tyr Arg Gln Ser Met Asn
     59 -10                  -5                  -1   1                  5
     61 aac ttc cag ggc ctc cgg agc ttt ggc tgc cgc ttc ggg acg tgc acg   512
     62 Asn Phe Gln Gly Leu Arg Ser Phe Gly Cys Arg Phe Gly Thr Cys Thr
     63              10                  15                  20
     65 gtg cag aag ctg gca cac cag atc tac cag ttc aca gat aag gac aag   560
     66 Val Gln Lys Leu Ala His Gln Ile Tyr Gln Phe Thr Asp Lys Asp Lys
```

```
                    RAW SEQUENCE LISTING                     DATE: 01/17/2002
                    PATENT APPLICATION:  US/10/018,924       TIME: 07:15:17

                    Input Set : A:\SO042PCTSEQ.txt
                    Output Set: N:\CRF3\01172002\J018924.raw

 67             25                       30                       35
 69 gac aac gtc gcc ccc agg agc aag atc agc ccc cag ggc tac ggc cgc    608
 70 Asp Asn Val Ala Pro Arg Ser Lys Ile Ser Pro Gln Gly Tyr Gly Arg
 71      40                       45                       50
 73 cgg cgc cgg cgc tcc ctg ccc gag gcc ggc ccg ggt cgg act ctg gtg    656
 74 Arg Arg Arg Arg Ser Leu Pro Glu Ala Gly Pro Gly Arg Thr Leu Val
 75  55                      60                       65                       70
 77 tct tct aag cca caa gca cac ggg gct cca gcc ccc ccg agt gga agt    704
 78 Ser Ser Lys Pro Gln Ala His Gly Ala Pro Ala Pro Pro Ser Gly Ser
 79                      75                       80                       85
 81 gct ccc cac ttt ctt taggatttag gcgcccatgg tacaaggaat agtcgcgcaa    759
 82 Ala Pro His Phe Leu
 83                 90
 85 gcatcccgct ggtgcctccc gggacgaagg acttcccgag cggtgtgggg accgggctct 819
 87 gacagccctg cggagaccct gagtccggga ggcaccgtcc ggcggcgagc tctggctttg 879
 89 caagggcccc tccttctggg ggcttcgctt ccttagcctt gctcaggtgc aagtgcccca 939
 91 gggggcgggg tgcagaagaa tccgagtgtt tgccaggctt aaggagagga gaaactgaga 999
 93 aatgaatgct gagacccccg gagcaggggt ctgagccaca gccgtgctcg cccacaaact 1059
 95 gatttctcac ggcgtgtcac ccccaccaggg cgcaagcctc actattactt gaactttcca 1119
 97 aaacctaaag aggaaaagtg caatgcgtgt tgtacataca gaggtaacta tcaatattta 1179
 99 agtttgttgc tgtcaagatt ttttttgtaa cttcaaatat agagatattt ttgtacgtta 1239
101 tatattgtat taagggcatt ttaaaagcaa ttatattgtc ctcccctatt ttaagacgtg 1299
103 aatgtctcag cgaggtgtaa agttgttcgc cgcgtggaat gtgagtgtgt ttgtgtgcat 1359
105 gaaagagaaa gactgattac ctcctgtgtg gaagaaggaa acaccgagtc tctgtataat 1419
107 ctatttacat aaaatgggtg atatgcgaac agcaaacc                          1457
110 <210> SEQ ID NO: 2
111 <211> LENGTH: 185
112 <212> TYPE: PRT
113 <213> ORGANISM: Homo sapiens
115 <400> SEQUENCE: 2
116 Met Lys Leu Val Ser Val Ala Leu Met Tyr Leu Gly Ser Leu Ala Phe
117                     -90                 -85                 -80
119 Leu Gly Ala Asp Thr Ala Arg Leu Asp Val Ala Ser Glu Phe Arg Lys
120                 -75                 -70                 -65
122 Lys Trp Asn Lys Trp Ala Leu Ser Arg Gly Lys Arg Glu Leu Arg Met
123             -60                 -55                 -50
125 Ser Ser Ser Tyr Pro Thr Gly Leu Ala Asp Val Lys Ala Gly Pro Ala
126     -45                 -40                 -35
128 Gln Thr Leu Ile Arg Pro Gln Asp Met Lys Gly Ala Ser Arg Ser Pro
129 -30                 -25                 -20                 -15
131 Glu Asp Ser Ser Pro Asp Ala Ala Arg Ile Arg Val Lys Arg Tyr Arg
132                     -10                  -5                  -1   1
134 Gln Ser Met Asn Asn Phe Gln Gly Leu Arg Ser Phe Gly Cys Arg Phe
135             5                   10                  15
137 Gly Thr Cys Thr Val Gln Lys Leu Ala His Gln Ile Tyr Gln Phe Thr
138     20                  25                  30
140 Asp Lys Asp Lys Asp Asn Val Ala Pro Arg Ser Lys Ile Ser Pro Gln
141  35                 40                  45                  50
143 Gly Tyr Gly Arg Arg Arg Arg Arg Ser Leu Pro Glu Ala Gly Pro Gly
```

RAW SEQUENCE LISTING DATE: 01/17/2002
PATENT APPLICATION: US/10/018,924 TIME: 07:15:17

Input Set : A:\SO042PCTSEQ.txt
Output Set: N:\CRF3\01172002\J018924.raw

```
144                  55                  60                  65
146 Arg Thr Leu Val Ser Ser Lys Pro Gln Ala His Gly Ala Pro Ala Pro
147              70                  75                  80
149 Pro Ser Gly Ser Ala Pro His Phe Leu
150          85                  90
153 <210> SEQ ID NO: 3
154 <211> LENGTH: 1493
155 <212> TYPE: DNA
156 <213> ORGANISM: Sus scrofa
158 <220> FEATURE:
159 <221> NAME/KEY: CDS
160 <222> LOCATION: (148)..(711)
162 <220> FEATURE:
W--> 163 <221> NAME/KEY: mat peptide
164 <222> LOCATION: (430)..(585)
166 <400> SEQUENCE: 3
167 gcggaacagc tcgagccttg ccacctctag tttcttacca cagcttggac gtcggggttt 60
169 tgccactgcc agagggacgt ctcagacttc atcttcccaa atcttggcag atcacccccc 120
171 tagcagggtc tgcacatctc agccggg atg aag ctg gtt ccc gta gcc ctc atg 174
172                              Met Lys Leu Val Pro Val Ala Leu Met
173                                                  -90
175 tac ctg ggc tcg ctc gcc ttc ctg ggc gct gac aca gct cgg ctc gac   222
176 Tyr Leu Gly Ser Leu Ala Phe Leu Gly Ala Asp Thr Ala Arg Leu Asp
177 -85                 -80                 -75                 -70
179 gtg gcg gca gag ttc cga aag aaa tgg aat aag tgg gct cta agt cgt   270
180 Val Ala Ala Glu Phe Arg Lys Lys Trp Asn Lys Trp Ala Leu Ser Arg
181                 -65                 -60                 -55
183 gga aaa aga gaa ctt cgg ctg tcc agc agc tac ccc acc ggg atc gcc   318
184 Gly Lys Arg Glu Leu Arg Leu Ser Ser Ser Tyr Pro Thr Gly Ile Ala
185             -50                 -45                 -40
187 gac ttg aag gcc ggg cct gcc cag act gtc att cgg ccc cag gat gtg   366
188 Asp Leu Lys Ala Gly Pro Ala Gln Thr Val Ile Arg Pro Gln Asp Val
189         -35                 -30                 -25
191 aag ggc tcc tct cgc agc ccc cag gcc agc att ccg gat gca gcc cgc   414
192 Lys Gly Ser Ser Arg Ser Pro Gln Ala Ser Ile Pro Asp Ala Ala Arg
193     -20                 -15                 -10
195 atc cga gtc aag cgc tac cgc cag agt atg aac aac ttc cag ggc ctg   462
196 Ile Arg Val Lys Arg Tyr Arg Gln Ser Met Asn Asn Phe Gln Gly Leu
197  -5              -1   1               5                  10
199 cgg agc ttc ggc tgt cgc ttt ggg acg tgc acc gtg cag aag ctg gcg   510
200 Arg Ser Phe Gly Cys Arg Phe Gly Thr Cys Thr Val Gln Lys Leu Ala
201              15                  20                  25
203 cac cag atc tac cag ttc acg gac aaa gac aag gac ggc gtc gcc ccc   558
204 His Gln Ile Tyr Gln Phe Thr Asp Lys Asp Lys Asp Gly Val Ala Pro
205          30                  35                  40
207 cgg agc aag atc agc ccc cag ggc tac ggc cgc cgg cgc cga cgc tct   606
208 Arg Ser Lys Ile Ser Pro Gln Gly Tyr Gly Arg Arg Arg Arg Arg Ser
209      45                  50                  55
211 ctg ccc gaa gcc agc ctg ggc cgg act ctg agg tcc cag gag cca cag   654
```

RAW SEQUENCE LISTING DATE: 01/17/2002
PATENT APPLICATION: US/10/018,924 TIME: 07:15:17

Input Set : A:\SO042PCTSEQ.txt
Output Set: N:\CRF3\01172002\J018924.raw

```
212 Leu Pro Glu Ala Ser Leu Gly Arg Thr Leu Arg Ser Gln Glu Pro Gln
213  60                  65                  70                  75
215 gcg cac ggg gcc ccg gcc tcc ccg gcg cat caa gtg ctc gcc act ctc   702
216 Ala His Gly Ala Pro Ala Ser Pro Ala His Gln Val Leu Ala Thr Leu
217                  80                  85                  90
219 ttt agg att taggcgccta ctgtggcagc agcgaacagt cgcgcatgca           751
220 Phe Arg Ile
222 tcatgccggc gcttcctggg gcgggggget tcccggagcc gagcccctca gcggctgggg 811
224 cccgggcaga gacagcattg agagaccgag agtccgggag gcacagacca gcggcgagcc 871
226 ctgcattttc aggaacccgt cctgcttgga ggcagtgttc tcttcggctt aatccagccc 931
228 gggtccccgg gtgggggtgg agggtgcaga ggaatccaaa ggagtgtcat ctgccaggct 991
230 cacggagagg agaaactgcg aagtaaatgc ttagaccccc aggggcaagg gtctgagcca 1051
232 ctgccgtgcc gcccacaaac tgatttctga aggggaataa ccccaacagg gcgcaagcct 1111
234 cactattact tgaactttcc aaaacctaga gaggaaaagt gcaatgtatg ttgtatataa 1171
236 agaggtaact atcaatattt aagtttgttg ctgtcaagat ttttttttgt aacttcaaat 1231
238 atagagatat ttttgtacgt tatatattgt attaagggca ttttaaaaca attgtattgt 1291
240 tcccctcccc tctattttaa tatgtgaatg tctcagcgag gtgtaacatt gtttgctgcg 1351
242 cgaaatgtga gagtgtgtgt gtgtgtgtgc gtgaaagaga gtctggatgc ctcttgggga 1411
244 agaagaaaac accatatctg tataatctat ttacataaaa tgggtgatat gcgaagtagc 1471
246 aaaccaataa actgtctcaa tg                                        1493
249 <210> SEQ ID NO: 4
250 <211> LENGTH: 188
251 <212> TYPE: PRT
252 <213> ORGANISM: Sus scrofa
254 <400> SEQUENCE: 4
255 Met Lys Leu Val Pro Val Ala Leu Met Tyr Leu Gly Ser Leu Ala Phe
256                 -90                 -85                 -80
258 Leu Gly Ala Asp Thr Ala Arg Leu Asp Val Ala Ala Glu Phe Arg Lys
259             -75                 -70                 -65
261 Lys Trp Asn Lys Trp Ala Leu Ser Arg Gly Lys Arg Glu Leu Arg Leu
262         -60                 -55                 -50
264 Ser Ser Ser Tyr Pro Thr Gly Ile Ala Asp Leu Lys Ala Gly Pro Ala
265     -45                 -40                 -35
267 Gln Thr Val Ile Arg Pro Gln Asp Val Lys Gly Ser Ser Arg Ser Pro
268 -30                 -25                 -20                 -15
270 Gln Ala Ser Ile Pro Asp Ala Ala Arg Ile Arg Val Lys Arg Tyr Arg
271                 -10                  -5                  -1   1
273 Gln Ser Met Asn Asn Phe Gln Gly Leu Arg Ser Phe Gly Cys Arg Phe
274           5                  10                  15
276 Gly Thr Cys Thr Val Gln Lys Leu Ala His Gln Ile Tyr Gln Phe Thr
277      20                  25                  30
279 Asp Lys Asp Lys Asp Gly Val Ala Pro Arg Ser Lys Ile Ser Pro Gln
280  35                  40                  45                  50
282 Gly Tyr Gly Arg Arg Arg Arg Arg Ser Leu Pro Glu Ala Ser Leu Gly
283                 55                  60                  65
285 Arg Thr Leu Arg Ser Gln Glu Pro Gln Ala His Gly Ala Pro Ala Ser
286             70                  75                  80
288 Pro Ala His Gln Val Leu Ala Thr Leu Phe Arg Ile
289           85                  90
```

RAW SEQUENCE LISTING DATE: 01/17/2002
PATENT APPLICATION: US/10/018,924 TIME: 07:15:17

Input Set : A:\SO042PCTSEQ.txt
Output Set: N:\CRF3\01172002\J018924.raw

```
    292 <210> SEQ ID NO: 5
    293 <211> LENGTH: 1376
    294 <212> TYPE: DNA
    295 <213> ORGANISM: Rattus norvegicus
    297 <220> FEATURE:
    298 <221> NAME/KEY: CDS
    299 <222> LOCATION: (154)..(708)
    301 <220> FEATURE:
W--> 302 <221> NAME/KEY: mat peptide
    303 <222> LOCATION: (433)..(582)
    305 <400> SEQUENCE: 5
    306 tccagccttt accgctcctg gtttctcggc ttctcatcgc agtcagtctt ggactttgcg 60
    308 ggttttgccg ctgtcagaag gacgtctcgg actttctgct tcaagtgctt gacaactcac 120
    310 cctttcagca gggtatcgga gcatcgctac aga atg aag ctg gtt tcc atc gcc  174
    311                                    Met Lys Leu Val Ser Ile Ala
    312                                                    -90
    314 ctg atg tta ttg ggt tcg ctc gcc gtt ctc ggc gcg gac acc gca cgg   222
    315 Leu Met Leu Leu Gly Ser Leu Ala Val Leu Gly Ala Asp Thr Ala Arg
    316     -85                 -80                 -75
    318 ctc gac act tcc tcg cag ttc cga aag aag tgg aat aag tgg gcg cta   270
    319 Leu Asp Thr Ser Ser Gln Phe Arg Lys Lys Trp Asn Lys Trp Ala Leu
    320 -70                 -65                 -60                 -55
    322 agt cgt ggg aag agg gaa cta caa gcg tcc agc agc tac cct acg ggg   318
    323 Ser Arg Gly Lys Arg Glu Leu Gln Ala Ser Ser Ser Tyr Pro Thr Gly
    324                 -50                 -45                 -40
    326 ctc gtt gat gag aag aca gtc ccg acc cag act ctt ggg ctc cag gac   366
    327 Leu Val Asp Glu Lys Thr Val Pro Thr Gln Thr Leu Gly Leu Gln Asp
    328             -35                 -30                 -25
    330 aag cag agc acg tct agc acc cca caa gcc agc act cag agc aca gcc   414
    331 Lys Gln Ser Thr Ser Ser Thr Pro Gln Ala Ser Thr Gln Ser Thr Ala
    332         -20                 -15                 -10
    334 cac att cga gtc aaa cgc tac cgc cag agc atg aac cag ggg tcc cgc   462
    335 His Ile Arg Val Lys Arg Tyr Arg Gln Ser Met Asn Gln Gly Ser Arg
    336      -5              -1   1                   5                  10
    338 agc act gga tgc cgc ttt ggg acc tgc aca atg cag aaa ctg gct cac   510
    339 Ser Thr Gly Cys Arg Phe Gly Thr Cys Thr Met Gln Lys Leu Ala His
    340                 15                  20                  25
    342 cag atc tac cag ttt aca gac aaa gac aag gac ggc atg gcc ccc aga   558
    343 Gln Ile Tyr Gln Phe Thr Asp Lys Asp Lys Asp Gly Met Ala Pro Arg
    344             30                  35                  40
    346 aac aag atc agc cct caa ggc tat ggc cgc cgg cgc cgg cgt tcc ctg   606
    347 Asn Lys Ile Ser Pro Gln Gly Tyr Gly Arg Arg Arg Arg Arg Ser Leu
    348         45                  50                  55
    350 cca gag gtc ctc cga gcc cgg act gtg gag tcc tcc cag gag cag aca   654
    351 Pro Glu Val Leu Arg Ala Arg Thr Val Glu Ser Ser Gln Glu Gln Thr
    352     60                  65                  70
    354 cac tca gct cca gcc tcc ccg gcg cac caa gac atc tcc aga gtc tct   702
    355 His Ser Ala Pro Ala Ser Pro Ala His Gln Asp Ile Ser Arg Val Ser
    356  75                  80                  85                  90
```

VERIFICATION SUMMARY DATE: 01/17/2002
PATENT APPLICATION: **US/10/018,924** TIME: 07:15:18

Input Set : **A:\SO042PCTSEQ.txt**
Output Set: **N:\CRF3\01172002\J018924.raw**

L:5 M:283 W: Missing Blank Line separator, <130> field identifier
L:7 M:270 C: Current Application Number differs, Replaced Application Number
L:8 M:271 C: Current Filing Date differs, Replaced Current Filing Date
L:26 M:257 W: Feature value mis-spelled or invalid, <221> Name/Key for SEQ ID#:1
L:163 M:257 W: Feature value mis-spelled or invalid, <221> Name/Key for SEQ ID#:3
L:302 M:257 W: Feature value mis-spelled or invalid, <221> Name/Key for SEQ ID#:5

DESCRIPTION

COMPOSITION FOR PROMOTING PASSIVE EXTENSION OF BLADDER SMOOTH MUSCLE

TECHNICAL FIELD

The present invention relates to a composition for promoting extension of smooth muscle of the urinary bladder, comprising adrenomedullin.

BACKGROUND ART

Urinary incontinence is a common but very severe condition which mostly causes patients to be embarrassed, encounter difficulties, and be driven to despair. Clearly, there is a strong demand for a reliable and safe method of treating urinary incontinence. To date such a demand has not been satisfied to an appropriate level.

Urinary incontinence refers to a condition in which urine involuntarily flows out during the storage phase, and which is caused when there is a functional or organic abnormality in one or both of the urinary bladder and the urethra. Urinary incontinence occurs when bladder smooth muscle is involuntarily contracted so that the internal pressure of the urinary bladder is increased, or when urethral closure pressure created by the urethral sphincter and a supporting tissue surrounding the urethra is too weak to repel the internal pressure of the normal urinary bladder. Urinary incontinence is divided into several types depending on the pathology. Broad types are: urge incontinence; reflex incontinence; overflow incontinence

(poorly compliant bladder), stress incontinence, total incontinence; and nocturnal enuresis.

Urge incontinence is a condition in which urine involuntarily flows out accompanying a strong urge to urinate, or after feeling an urge to urinate, a patient cannot resist urine outflow and wets before reaching a toilet. These are divided into motor and sensory types. Motor urge incontinence is caused by a disorder of an inhibitory pathway for the micturition reflex, or excitation of an exitatory pathway, a representative example of which is neurogenic bladder due to a lesion, such as for example a cerebrovascular disorder and a brain tumor. Representative examples of sensory urge incontinence include cystitis and urethritis.

Reflex incontinence is a condition in which when the urinary bladder is filled with urine to some extent without a normal urge to urinate, the urinary bladder is reflectively contracted, so that urine involuntarily flows out. Reflex incontinence includes neurogenic bladder due to injury of the spinal cord above the urination center in the sacral spinal cord, urinary incontinence of infants, and the like.

Overflow incontinence is a condition in which since urine cannot be sufficiently excreted, the urinary bladder is excessively filled with urine and the urine gradually flows out. Overflow incontinence includes neurogenic bladder (poorly compliant bladder) due to injury of peripheral nerves, and disorders of the passage of the lower urinary tract due to prostatic hypertrophy or cancer.

Stress incontinence is a symptom in which when a

patient strains in sneezing or coughing, laughs, runs, or the like, so that abdominal pressure is rapidly increased, urine flows out without contraction of the urinary bladder. The increase in the abdominal pressure leads to a raise in the internal pressure of the urinary bladder. In this case, if the increased internal pressure exceeds the urethral closure pressure, urine flows out. Females more often suffer from this disorder. A major cause of stress incontinence is that supporting tissues surrounding the urethra are seriously weakened by parturition or aging, so that urethral closure pressure cannot be sufficiently generated.

Total incontinence is a condition characterized by dysfunction of the urethral sphincter, and in which urine flows out from the urethra at all times irrespective of the presence or absence of abdominal pressure. The cause of total incontinence is injury of the urethral sphincter caused by trauma of the pelvis or surgery of the prostate.

Nocturnal enuresis is also called bed-wetting, which is a condition in which patients of 4 or more years old, which is the age at which the habit of urinating is established, unconsciously void urine during sleep though they do not have an organic abnormality in the urinary tract or the nerve system and can urinate normally (no urinary incontinence) on awakening. This disorder is caused by the premature inhibitory mechanism of the central nerve system for the micturition reflex.

At present, anticholinergic agents are generally used for treatment of the following patients having urine storage disorders: (1) neurogenic bladder patients who have

urinary incontinence due to the hyperactivity of urinary bladder and involuntarily urinate; (2) neurogenic bladder patients who do not have abnormal urinary bladder contraction but have a poorly compliant urinary bladder in which the internal pressure of the urinary bladder gradually increased as urine is filled; (3) one subset of patients who chiefly complain of pollakiuria; etc. Clinically, despite the efficacy of anticholinergic agents against urine storage disorders, when the anticholinergic agents are actually used, urinary bladder contraction is inhibited in urination so that urination disorders are often exacerbated to cause side effects, such as increased residual urine and anuresis.

As described above, clearly, urinary incontinence is one of today's major diseases, but current therapeutic methods are not satisfactory. There is a demand for a novel drug for treating urinary incontinence. The term "urination disorder" as used herein refers to an abnormal urination condition, such as urinary incontinence, caused by insufficient extension of bladder smooth muscle. Examples of urination disorders include urinary incontinence (e.g., urge incontinence), frequent urination, nocturnal pollakiuria. An agent capable of promoting extension of bladder smooth muscle would be expected to help bladder smooth muscle extend during storage phase to reduce the internal pressure of the urinary bladder. Thus, such an agent would be considered to be useful as drugs for treatment of urinary incontinence and other symptoms relating to urination.

It has been known that adrenomedullin has a vasodilatory action. For example, Nakamura et al., Jpn. J.

Pharmacol. 67, 259-262 (1995) has reported in Figure 1 that contracted mesenteric artery is extended by addition of adrenomedullin in a concentration-dependent manner. However, vasodilation cannot be considered to be identical with passive extension of muscle of the urinary bladder. For example, Nishimura et al., British J. Pharmacology, 120, 193-200 (1997) describes in Figure 6 that addition of adrenomedullin to the urinary bladder does not cause contraction or extension (active extension) of the urinary bladder.

The present invention is intended to solve the above-described problems. The objective of the present invention is to provide a novel agent for promoting passive extension of bladder smooth muscle.

DISCLOSURE OF THE INVENTION

The inventions found that adrenomedullin originally identified as a peptide having a hypotensive action does not directly extend bladder smooth muscle, but has an action of promoting passive extension of the urinary bladder wall due to urine storage (i.e., an action of promoting extension of bladder smooth muscle) and based on that finding, completed the present invention.

Adrenomedullin does not inhibit contraction of the urinary bladder due to acetylcholine (i.e., urinary bladder contraction in urination) and therefore, can provide a therapeutic agent for ameliorating a urine storage disorder without inhibiting urinary bladder contraction in urination and substantially without side effects.

A composition of the present invention for promoting passive extension of bladder smooth muscle comprises adrenomedullin. The composition may be used to ameliorate a urination disorder. The urination disorder may be a urinary incontinence selected from the group consisting of urge incontinence, reflex incontinence, and overflow incontinence.

In one embodiment, the adrenomedullin may be any of the following peptides: (a) a petpide comprising an amino acid sequence from Ser in position 13 to Tyr in position 52 of SEQ ID NO: 2 in SEQUENCE LISTING; (b) a peptide comprising an amino acid sequence having one or several amino acid deleted, substituted, or added in the amino acid sequence (a), and having an action of promoting extension of bladder smooth muscle; (c) a petpide comprising an amino acid sequence from Tyr in position 1 to Tyr in position 52 of SEQ ID NO: 2 in SEQUENCE LISTING; (d) a peptide comprising an amino acid sequence having one or several amino acid deleted, substituted, or added in the amino acid sequence (c), and having an action of promoting extension of bladder smooth muscle; (e) a petpide comprising an amino acid sequence from Ala in position -73 to Tyr in position 52 of SEQ ID NO: 2 in SEQUENCE LISTING; (f) a peptide comprising an amino acid sequence having one or several amino acid deleted, substituted, or added in the amino acid sequence (e), and having an action of promoting extension of bladder smooth muscle; (g) a petpide comprising an amino acid sequence from Met in position -94 to Leu in position 91 of SEQ ID NO: 2 in SEQUENCE LISTING; and (h) a peptide comprising an amino acid sequence having one or several amino acid deleted, substituted, or added in the amino acid sequence (g), and having an action of promoting extension

of bladder smooth muscle.

In another embodiment, the C-terminus of the adrenomedullin may be amidated. Gly may be added to the C-terminus of the adrenomedullin.

In another embodiment, in the adrenomedullin, Cys in position 16 and Cys in position 21 of SEQ ID NO: 2 in SEQUENCE LISTING may be crosslinked. The crosslink may be a disulfide bond or a $-CH_2-CH_2-$ bond.

A method of the present invention for ameliorating a urination disorder uses a composition comprising adrenomedullin.

The present invention also provides use of adrenomedullin in production of a drug for ameliorating a urination disorder.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure **1** is a schematic diagram showing a method for dissecting the urinary bladder. As shown in Figure **1(a)**, ends of the urinary bladder were cut off along solid lines, and the urinary bladder was cut open along dashed lines. Four urinary bladder sections were obtained from the cut-open urinary bladder along three solid lines as shown in Figure **1(b)**.

Figure **2** is a graph showing the results of measurement of the effect of adrenomedullin on extension of the urinary bladder where the applied tension is 1 g. White circles indicate controls, while black circles

indicate the case of addition of adrenomedullin.

Figure 3 is a graph showing the results of measurement of the effect of adrenomedullin on contraction of the urinary bladder due to acetylcholine.

Figure 4 is a diagram showing the amino acid sequence of adrenomedullin derived from human pheochromocytoma. RE1 to RE6 indicate fragments produced by digesting the amino acid sequence with arginylendopeptidase.

BEST MODE FOR CARRYING OUT THE INVENTION

When carrying out the present invention, protein separation and analysis methods, recombinant DNA techniques, and assays, which are known in the art, may be employed unless otherwise specified.

I. Definition

Hereinafter, the terms used herein to explain the present invention will be described.

An "adrenomedullin" is a peptide having a hypotensive action, originally isolated from human pheochromocytoma. The term "adrenomedullin" as used herein is not limited to the particular peptide, but includes peptides having substantial homology in the amino acid sequence with that peptide. Examples of the homologous peptides include species mutants and allelic mutants. Human-derived adrenomedullin comprises an amino acid sequence from Tyr in position 1 to Tyr in position 52 of SEQ ID NO: 2 in SEQUENCE LISTING. (The peptide consisting

of an amino acid sequence from Met in position -94 to Leu in position 91 of SEQ ID NO: 2 in SEQUENCE LISTING is believed to be preproadrenomedullin. The peptide obtained by processing of a signal peptide and consisting of an amino acid sequence from Ala in position -73 to Leu in position 91 of SEQ ID NO: 2 in SEQUENCE LISTING is believed to be proadrenomedullin. The peptide consists of an amino acid sequence from Ser in position 13 to Tyr in position 52 of SEQ ID NO: 2 in SEQUENCE LISTING is an adrenomedullin fragment which has been confirmed to have a hypotensive action. Adrenomedullin in any of the above-described forms may be employed in the present invention.) Human-derived adrenomedullin may be encoded by a polynucleotide sequence from T in position 447 to C in position 602 of SEQ ID NO: 1 in SEQUENCE LISTING.

Porcine-derived adrenomedullin comprises an amino acid sequence from Tyr in position 1 to Tyr in position 52 of SEQ ID NO: 4 in SEQUENCE LISTING. Porcine-derived adrenomedullin may be encoded by a polynucleotide sequence from T in position 430 to C in position 585 of SEQ ID NO: 3 in SEQUENCE LISTING. Rat-derived adrenomedullin comprises an amino acid sequence from Tyr in position 1 to Tyr in position 50 of SEQ ID NO: 6 in SEQUENCE LISTING. Rat-derived adrenomedullin may be encoded by a polynucleotide sequence from T in position 433 to T in position 582 of SEQ ID NO: 5 in SEQUENCE LISTING.

Clearly, human-derived peptides are preferable for human diseases or treatment of a human. However, homologous peptides derived from other mammals may also be employed for some purposes. Further, comparison of human-derived peptides with peptides derived from other mammals is

important when an attempt is made to obtain a variant maintaining a desired activity of a human-derived peptide.

Adrenomedullin used in the present invention is not necessarily limited to the above-described sequences, but includes, as subjects, homologous peptides having an amino acid sequence which has one or several amino acid deleted, substituted, or added in the above-described sequences and maintaining a desired activity.

Amino acid conservative substitution is one preferable means for obtaining homologous peptides. Conservative substitution representatively includes substitutions conducted within the following groups: glycine, alanine; valine, isoleucine, leucine; aspartic acid, glutamic acid; asparagine, glutamine; serine, threonine; lysine, arginine; and phenylalanine, tyrosine.

The homology between two amino acid sequences is determined by optionally introducing a gap to optimize residue matching. A peptide having an amino acid sequence, which has substantially homology with the amino acid sequence of human adrenomedullin, has representatively about 60% homology with the amino acid sequence of human adrenomedullin, preferably at least about 70%, more preferably at least about 80%, and in an especially preferable embodiment, at least about 90% or more. Software for determining homology is easily available.

In the present invention, a peptide is by definition referred to "have an action of promoting extension of bladder smooth muscle" if the degree of extention of the urinary bladder is about 80% or more and preferably about 90% or

more of the value indicated in the experimental sample of Example 1 described below when measured under substantially the same conditions as those of Example 1 below.

The C-terminus of a peptide used in the present invention may or may not be amidated. "Amidation of C-terminus" refers to one of modification reactions of a peptide, in which the COOH group of the C-terminal amino acid of a peptide is changed to the form of $CONH_2$. A number of biologically active peptides functioning in vivo are first biosynthesized as a precursor protein having a larger molecular weight. The precursor protein is then matured by a modification reaction such as for example the amidation of the C-terminus. The amidation is conducted by a C-terminal amidating enzyme acting on the precursor protein. The precursor protein always includes a Gly residue on the C-terminal side of a residue to be amidated, which is frequently followed by a basic amino acid sequence pair, such as for example Lys-Arg or Arg-Arg, on the C-terminal side (Mizuno, Seikagaku, Vol. 61, No. 12, pp. 1435-1461 (1989)).

II. Adrenomedullin having an action of promoting extension of bladder smooth muscle

In the present invention, adrenomedullin is utilized as an effective component of a composition for promoting extension of bladder smooth muscle. Adrenomedullin is utilized as an effective component for manufacturing a drug for ameliorating a urination disorder. Adrenomedullin may be isolated from naturally-occurring sources, produced using recombinant DNA techniques, or chemically synthesized.

When adrenomedullin is isolated from naturally-occurring sources, purification may be conducted, for example, in the following way. For example, firstly human pheochromocytoma is pulverized to obtain a crude extract which is in turn subjected to various chromatography techniques for purification. In this case, by monitoring an increase in the cAMP activity of platelets, a fraction containing adrenomedullin of interest can be obtained. Method for isolation and purification of adrenomedullin are described in Japanese Laid-Open Publication No. 7-196693.

When adrenomedullin is produced using recombinant DNA techniques, the DNA sequence encoding a peptide of interest is expressed using various recombinant systems. Construction of expression vectors and preparation of transformants having appropriate DNA sequences are conducted by methods known in the art. Expression may be conducted using prokaryote systems or eukaryote systems.

Prokaryote hosts used include E.coli, bacillus, and other bacteria. For such prokaryote hosts, plasmid vectors having replication sites and control sequences compatible with the hosts are used. For example, E.coli is typically transformed with a derivative of pBR322 which is a plasmid derived from E.coli. The control sequence herein is defined to include a promoter for initiation of transcription, an operator if necessary, and a ribosome binding site. Such a control sequence includes generally used promoters such as for example β-lactamase and lactose promoter systems (Chang et al., Nature (1977) 198, 1056), tryptophan promoters (Goeddel et al., Nucleic Acids Res., (1980) 8: 4057), and P_L promoters derived from λ and N-gene ribosome binding sites (Shimatake, Nature (1981) 292, 128).

As a eukaryote host, yeast is used, for example. For such a host eukaryote, a plasmid vector having a replication site and a control sequence compatible with the host is used. For example, yeast is transformed with pYEUra3 (Clontech). Other promoters useful in a yeast host include, for example, promoter classes for synthesizing a glycolytic enzyme, such as for example a promoter for 3-phosphoglycerate kinase (Hitzeman et al., J. Biol. Chem. (1980) 255, 2073). Other promoters include those derived from an enolase gene or those derived from a Leu2 gene obtained from YEp13.

Appropriate mammalian promoters include metallothionein, an early or late promoter derived from SV40, and other virus promoters such as for example those derived from polyoma virus, adenovirus II, bovine papilloma virus and avian sarcoma virus.

A transformant can be obtained by introducing an expression vector into an appropriate host cell. A desired adrenomedullin can be obtained by culturing the transformant under appropriate conditions.

Chemical synthesis of adrenomedullin may be conducted within a method known in the art. For example, adrenomedullin may be synthesized by a solid phase method using a peptide synthesizer. A C-terminal amidated peptide can be synthesized on a peptide synthesizer by condensing amino acids sequentially from the C-terminal amino acid to the N-terminal amino acid using a benzhydryl amine resin and a standard DCC/HOBt, and cutting out an intended peptide from the resultant peptide resin by a standard cleavage

method (trifluoromethanesulfonic acid method).

A C-terminal amidated adrenomedullin may be obtained by one of the following: a carboxyl group at the C-terminus of the peptide obtained by expression in a host is chemically amidated; or a peptide is prepared so as to have Gly added to the C-terminus of an intended amino acid sequence, and is then allowed to react with the above-mentioned C-terminal amidating enzyme for amidation.

Alternatively, the peptide obtained by adding Gly to the C-terminus of adrenomedullin may be amidated due to an action of a C-terminal amidating enzyme in vivo as described above.

A disulfide bond can be formed, for example, by oxidizing a peptide by air oxidization or with an appropriate oxidant. The substitution of the disulfide bond can be conducted with a $-CH_2-CH_2-$ bond by a well-known method (O. Keller et al., Helv. Chim. Acta (1974) 57: 1253). Generally, cleavage in the disulfide bond is avoided by substituting a $-CH_2-CH_2-$ bond for the disulfide bond, resulting in stabilization of the protein.

Assay methods for action of promoting extension of bladder smooth muscle, which are known in the art, may be used to confirm that the thus-obtained adrenomedullin has an action of promoting extension of bladder smooth muscle. Examples of such assays include a method employing the urinary bladder isolated from any animal, and a method of measuring the internal pressure of the urinary bladder under anesthetization. When the urinary bladder isolated from a rat is used, for example, action of promoting extension of

bladder smooth muscle may be assayed under the following conditions. The urinary bladder is isolated from a rat and cut into several pieces to obtain urinary bladder strips. While the resultant urinary bladder strips are immersed in a buffer solution, such as for example Tyrode's solution, extension or contraction of the urinary bladder is continuously examined using a measuring apparatus, such as for example an isometric transducer and an isotonic transducer. The urinary bladder is allowed to be extended in the presence or absence of a subject peptide, and extension of the urinary bladder is compared between the two cases to judge whether or not the peptide has an action of promoting extension of bladder smooth muscle.

III. Preparation of a composition for promoting extension of bladder smooth muscle

A composition of the present invention comprises an effective amount of adrenomedullin and may further comprise any excipient known to those skilled in the art. Examples of the excipients include lactose, cornstarch, magnesium stearate, and alum.

The composition of the present invention is prepared in accordance with methods known in the art.

The composition of the present invention may be in any form. The composition of the present invention may be a solid, such as for example a tablet, a pill, a capsule, and a granule; or a liquid, such as for example an aqueous solution and a suspension. When the composition of the present invention is orally administered as a tablet, an excipient, such as for example lactose, cornstarch, and magnesium stearate, may be commonly used. When the

composition of the present invention is orally administered as a capsule, an excipient, such as for example lactose and dried cornstarch, may be commonly used. In order to orally administer adrenomedullin as an aqueous suspension, the adrenomedullin may be used in combination with an emulsion or a suspension. The aqueous suspension may optionally contain a sweetner and an aroma chemical. When the composition of the present invention is intramuscularly, intraperitoneally, subcutaneously, or intravenously injected, adrenomedullin is dissolved in a sterilized solution to prepare a buffer solution which is in turn adjusted into an appropriate pH. When the composition of the present invention is intravenously administered, the composition is preferably isotonic.

The composition of the present invention may be used as a drug for ameliorating a urination disorder.

IV. Administration of a composition for promoting extension of bladder smooth muscle

The composition of the present invention may be administered in the form of a conventional peptide formulation as described in Remington's Pharmaceutical Sciences, Mack Publishing, Easton, PA. For example, the composition of the present invention may be administered orally, or alternatively parenterally, such as for example intravenous administration, intramuscular injection, intraperitoneal injection, and subcutaneous injection. The peptide may be administered by injection into the urinary bladder.

When the composition of the present invention is administered into a human subject, typically, the dose per

day can be appropriately determined by those skilled in the art by taking into consideration a patient's symptoms, severity, individual differences in sensitivity, weight, age, and the like. The composition of the present invention may be administered once a day or several times a day.

Urination disorders would be ameliorated by administration of the composition of the present invention.

(Examples)

Hereinafter, the action of adrenomedullin of the present invention as a drug for promoting extension of bladder smooth muscle will be more specifically described. The present invention is not limited to the following examples. Adrenomedullin used in the examples is a synthesized peptide consisting of an amino acid sequence from Tyr in position 1 to Tyr in position 50 of SEQ ID NO: 6 (available from Peptide Institute, Inc.).

(Example 1: Effect of adrenomedullin on extension of the urinary bladder of a male rat)

8 to 16 weeks old male rats were sacrificed by hammering their heads. Thereafter, the rats were decapitated, followed by exsanguination. The urinary bladders were isolated from the rats. Each isolated urinary bladder was cut into four portions, thereby obtaining urinary bladder strips (Figure 1).

The effect of adrenomedullin on the rat urinary bladder was examined by measuring contractions of the urinary bladder strips using an isotonic transducer TD-112S (manufactured Nippon Kohden Corporation) where the tension was 1 g.

The urinary bladder strips were firstly immersed in 30 ml of Tyrode's solution with 100 nM adrenomedullin (experimental sample) or without it (control sample). In this situation, the sections were attached to the isometric transducer where the tension was 1 g, to continuously measure relaxation of the urinary bladder. The composition of the Tyrode's solution is as follows: 139 mM NaCl, 2.7 mM KCl, 11.9 mM $NaHCO_3$, 2.6 mM $MgCl_2 \cdot 6H_2O$, 0.4 mM $NaH_2PO_4 \cdot 2H_2O$, 1.7 mM $CaCl_2$, and 5.5 mM glucose; pH 7.4).

The above-described experiment was repeated five times. The results are shown in Figure 2. Solid colored circles indicate the results of the experimental sample, while plain circles indicate averages of the control sample. Vertical bars indicate the standard deviation of a two-way analysis of variance. The vertical axis indicates the length of relaxation (mm), while the horizontal axis indicate time (minutes).

As shown in Figure 2, when tension was applied to the urinary bladder in the presence of adrenomedullin to cause the urinary bladder to be extended, the result obtained is that the urinary bladder wall was more extended compared to the case of the absence of adrenomedullin. Normally, the urinary bladder is passively extended by urine filling therein during the urine storage phase, and the extension prevents the internal pressure of the urinary bladder from being increased, so that the internal pressure of the urinary bladder remains at a constant low value. A high expansibility of the urinary bladder is referred to as a high level of compliance. As a result of this example, it was demonstrated that adrenomedullin causes the urinary

bladder to remain in a higher compliance state during the urine storage phase, thereby increasing the capacity of the urinary bladder.

(Example 2: Effect of adrenomedullin on static tension, and contraction due to acetylcholine of the urinary bladder of a male rat)

Urinary bladder strips were prepared in a manner similar to that of Example 1. The urinary bladder sections were attached to an isometric transducer FD pickup TB611T (manufactured by Nippon Kohden Corporation) in Tyrode's solution. Contraction of the urinary bladder was continuously measured. Firstly, 30 nM to 1 mM acetylcholine was added to the Tyrode's solution. As a result, contraction of the urinary bladder occurred (Figure 3). In Figure 3, the vertical axis indicates tension (unit: g), while the horizontal axis indicates time. Contraction induced by acetylcholine was confirmed, followed by washing out acetylcholine. Thereafter, 100 nM adrenomedullin was added to the Tyrode's solution. As a result, the urinary bladder was not contracted. Further, 30 nM to 1 mM acetylcholine was added to the Tyrode's solution. As a result, recontraction of the urinary bladder occured. The contraction induced by acetylcholine alone before the addition of adrenomedullin was not significantly different from the contraction induced by acetylcholine in the presence of adrenomedullin.

Therefore, the tested adrenomedullin did not affect the static tension of the urinary bladder, or exhibit an effect of preventing contraction of the urinary bladder due to acetylcholine, which is believed to correspond to contraction of the urinary bladder during a voiding phase.

INDUSTRIAL APPLICABILITY

According to the present invention, a composition for promoting extension of bladder smooth muscle, comprising adrenomedullin is provided. Such a composition is useful for ameliorating a urination disorder selected from the group consisting of urge incontinence, reflex incontinence, and overflow incontinence.

CLAIMS

1. A composition for promoting passive extension of bladder smooth muscle, comprising adrenomedullin.

2. A composition according to claim 1, used to ameliorate a urination disorder.

3. A composition according to claim 2, wherein the urination disorder is a urinary incontinence selected from the group consisting of urge incontinence, reflex incontinence, and overflow incontinence.

4. A composition according to claim 1, wherein the adrenomedullin is:

(a) a petpide comprising an amino acid sequence from Ser in position 13 to Tyr in position 52 of SEQ ID NO: 2 in SEQUENCE LISTING; or

(b) a peptide comprising an amino acid sequence having one or several amino acid deleted, substituted, or added in the amino acid sequence (a), and having an action of promoting extension of bladder smooth muscle.

5. A composition according to claim 4, wherein the adrenomedullin is:

(c) a petpide comprising an amino acid sequence from Tyr in position 1 to Tyr in position 52 of SEQ ID NO: 2 in SEQUENCE LISTING; or

(d) a peptide comprising an amino acid sequence having one or several amino acid deleted, substituted, or added in the amino acid sequence (c), and having an action of promoting extension of bladder smooth muscle.

6. A composition according to claim 5, wherein the adrenomedullin is:

(e) a petpide comprising an amino acid sequence from Ala in position -73 to Tyr in position 52 of SEQ ID NO: 2 in SEQUENCE LISTING; or

(f) a peptide comprising an amino acid sequence having one or several amino acid deleted, substituted, or added in the amino acid sequence (e), and having an action of promoting extension of bladder smooth muscle.

7. A composition according to claim 6, wherein the adrenomedullin is:

(g) a petpide comprising an amino acid sequence from Met in position -94 to Leu in position 91 of SEQ ID NO: 2 in SEQUENCE LISTING; or

(h) a peptide comprising an amino acid sequence having one or several amino acid deleted, substituted, or added in the amino acid sequence (g), and having an action of promoting extension of bladder smooth muscle.

8. A composition according to any of claims 1 and 4 to 7, wherein the C-terminus of the adrenomedullin is amidated.

9. A composition according to any of claims 1 and 4 to 7, wherein Gly is added to the C-terminus of the adrenomedullin.

10. A composition according to any of claims 1 and 4 to 7, wherein in the adrenomedullin, Cys in position 16 and Cys in position 21 of SEQ ID NO: 2 in SEQUENCE LISTING are crosslinked.

11. A composition according to claim 10, wherein the crosslink is a disulfide bond.

12. A composition according to claim 10, wherein the crosslink is a $-CH_2-CH_2-$ bond.

13. A method for ameliorating a urination disorder using a composition comprising adrenomedullin.

14. Use of adrenomedullin in production of a drug for ameliorating a urination disorder.

FIG. 1



FIG. 2


Time (minutes)
0
30
60
90
0
-2
-4
-6
-8
-10
Relaxation (mm)
Control
AM 100 nM

FIG. 3



* Contraction induced by addition of acetylcholine is not significantly influenced by the presence of adrenomedullin.

Static tension is not changed by adrenomedullin alone.

FIG. 4


1
10
Tyr–Arg–Gln–Ser–Met–Asn–Asn–Phe–Gln–Gly–Leu–Arg–Ser–Phe–Gly–
RE1
RE2
RE3
20
30
Cys–Arg–Phe–Gly–Thr–Cys–Thr–Val–Gln–Lys–Leu–Ala–His–Gln–Ile–
RE4
40
Tyr–Gln–Phe–Thr–Asp–Lys–Asp–Lys–Asp–Asn–Val–Ala–Pro–Arg–Ser–
RE5
50
52
Lys–Ile–Ser–Pro–Gln–Gly–Tyr–NH2
RE6

SEQUENCE LISTING

<110> Shionogi & Co., Ltd

<120> Composition for promoting passive extension of bladder smooth muscle

<130> S0042PCT

<140>

<141>

<150> JP P1999-177549

<151> 1999-06-23

<160> 6

<170> PatentIn Ver. 2.0

<210> 1

<211> 1457

<212> DNA

<213> Homo sapiens

<220>

<221> CDS

<222> (165)..(719)

<220>

<221> mat peptide

<222> (447)..(602)

<400> 1

ggcacgagct ggatagaaca gctcaagcct tgccacttcg ggcttctcac tgcagctggg 60

cttggacttc ggagttttgc cattgccagt gggacgtctg agactttctc cttcaagtac 120

ttggcagatc actctcttag cagggtctgc gcttcgcagc cggg atg aag ctg gtt 176
Met Lys Leu Val

```
tcc gtc gcc ctg atg tac ctg ggt tcg ctc gcc ttc cta ggc gct gac   224
Ser Val Ala Leu Met Tyr Leu Gly Ser Leu Ala Phe Leu Gly Ala Asp
-90                 -85                 -80                 -75

acc gct cgg ttg gat gtc gcg tcg gag ttt cga aag aag tgg aat aag   272
Thr Ala Arg Leu Asp Val Ala Ser Glu Phe Arg Lys Lys Trp Asn Lys
               -70                 -65                 -60

tgg gct ctg agt cgt ggg aag agg gaa ctg cgg atg tcc agc agc tac   320
Trp Ala Leu Ser Arg Gly Lys Arg Glu Leu Arg Met Ser Ser Ser Tyr
           -55                 -50                 -45

ccc acc ggg ctc gct gac gtg aag gcc ggg cct gcc cag acc ctt att   368
Pro Thr Gly Leu Ala Asp Val Lys Ala Gly Pro Ala Gln Thr Leu Ile
       -40                 -35                 -30

cgg ccc cag gac atg aag ggt gcc tct cga agc ccc gaa gac agc agt   416
Arg Pro Gln Asp Met Lys Gly Ala Ser Arg Ser Pro Glu Asp Ser Ser
   -25                 -20                 -15

ccg gat gcc gcc cgc atc cga gtc aag cgc tac cgc cag agc atg aac   464
Pro Asp Ala Ala Arg Ile Arg Val Lys Arg Tyr Arg Gln Ser Met Asn
-10                 -5                  -1  1                5

aac ttc cag ggc ctc cgg agc ttt ggc tgc cgc ttc ggg acg tgc acg   512
Asn Phe Gln Gly Leu Arg Ser Phe Gly Cys Arg Phe Gly Thr Cys Thr
            10                  15                  20

gtg cag aag ctg gca cac cag atc tac cag ttc aca gat aag gac aag   560
Val Gln Lys Leu Ala His Gln Ile Tyr Gln Phe Thr Asp Lys Asp Lys
        25                  30                  35

gac aac gtc gcc ccc agg agc aag atc agc ccc cag ggc tac ggc cgc   608
Asp Asn Val Ala Pro Arg Ser Lys Ile Ser Pro Gln Gly Tyr Gly Arg
    40                  45                  50
```

cgg cgc cgg cgc tcc ctg ccc gag gcc ggc ccg ggt cgg act ctg gtg 656
Arg Arg Arg Arg Ser Leu Pro Glu Ala Gly Pro Gly Arg Thr Leu Val
55 60 65 70

tct tct aag cca caa gca cac ggg gct cca gcc ccc ccg agt gga agt 704
Ser Ser Lys Pro Gln Ala His Gly Ala Pro Ala Pro Pro Ser Gly Ser
75 80 85

gct ccc cac ttt ctt taggatttag gcgcccatgg tacaaggaat agtcgcgcaa 759
Ala Pro His Phe Leu
90

gcatcccgct ggtgcctccc gggacgaagg acttcccgag cggtgtgggg accgggctct 819

gacagccctg cggagaccct gagtccggga ggcaccgtcc ggcggcgagc tctggctttg 879

caagggcccc tccttctggg ggcttcgctt ccttagcctt gctcaggtgc aagtgcccca 939

gggggcgggg tgcagaagaa tccgagtgtt tgccaggctt aaggagagga gaaactgaga 999

aatgaatgct gagacccccg gagcaggggt ctgagccaca gccgtgctcg cccacaaact 1059

gatttctcac ggcgtgtcac cccaccaggg cgcaagcctc actattactt gaactttcca 1119

aaacctaaag aggaaaagtg caatgcgtgt tgtacataca gaggtaacta tcaatattta 1179

agtttgttgc tgtcaagatt ttttttgtaa cttcaaatat agagatattt ttgtacgtta 1239

tatattgtat taagggcatt ttaaaagcaa ttatattgtc ctcccctatt ttaagacgtg 1299

aatgtctcag cgaggtgtaa agttgttcgc cgcgtggaat gtgagtgtgt ttgtgtgcat 1359

gaaagagaaa gactgattac ctcctgtgtg gaagaaggaa acaccgagtc tctgtataat 1419

ctatttacat aaaatgggtg atatgcgaac agcaaacc 1457

<210> 2
<211> 185
<212> PRT
<213> Homo sapiens

<400> 2

```
Met Lys Leu Val Ser Val Ala Leu Met Tyr Leu Gly Ser Leu Ala Phe
               -90                 -85                 -80

Leu Gly Ala Asp Thr Ala Arg Leu Asp Val Ala Ser Glu Phe Arg Lys
           -75                 -70                 -65

Lys Trp Asn Lys Trp Ala Leu Ser Arg Gly Lys Arg Glu Leu Arg Met
       -60                 -55                 -50

Ser Ser Ser Tyr Pro Thr Gly Leu Ala Asp Val Lys Ala Gly Pro Ala
   -45                 -40                 -35

Gln Thr Leu Ile Arg Pro Gln Asp Met Lys Gly Ala Ser Arg Ser Pro
-30                 -25                 -20                 -15

Glu Asp Ser Ser Pro Asp Ala Ala Arg Ile Arg Val Lys Arg Tyr Arg
               -10                 -5                  -1   1

Gln Ser Met Asn Asn Phe Gln Gly Leu Arg Ser Phe Gly Cys Arg Phe
         5                  10                  15

Gly Thr Cys Thr Val Gln Lys Leu Ala His Gln Ile Tyr Gln Phe Thr
     20                  25                  30

Asp Lys Asp Lys Asp Asn Val Ala Pro Arg Ser Lys Ile Ser Pro Gln
 35                  40                  45                  50

Gly Tyr Gly Arg Arg Arg Arg Arg Ser Leu Pro Glu Ala Gly Pro Gly
                55                  60                  65
```

Arg Thr Leu Val Ser Ser Lys Pro Gln Ala His Gly Ala Pro Ala Pro
70 75 80

Pro Ser Gly Ser Ala Pro His Phe Leu
85 90

<210> 3
<211> 1493
<212> DNA
<213> Sus scrofa

<220>
<221> CDS
<222> (148)..(711)

<220>
<221> mat peptide
<222> (430)..(585)

<400> 3
gcggaacagc tcgagcctig ccacctctag tttcttacca cagcttggac gtcggggttt 60

tgccactgcc agagggacgt ctcagacttc atcttcccaa atcttggcag atcacccccc 120

tagcagggtc tgcacatctc agccggg atg aag ctg gtt ccc gta gcc ctc atg 174
Met Lys Leu Val Pro Val Ala Leu Met
-90

tac ctg ggc tcg ctc gcc ttc ctg ggc gct gac aca gct cgg ctc gac 222
Tyr Leu Gly Ser Leu Ala Phe Leu Gly Ala Asp Thr Ala Arg Leu Asp
-85 -80 -75 -70

gtg gcg gca gag ttc cga aag aaa tgg aat aag tgg gct cta agt cgt 270
Val Ala Ala Glu Phe Arg Lys Lys Trp Asn Lys Trp Ala Leu Ser Arg

```
                -65                 -60                 -55

gga aaa aga gaa ctt cgg ctg tcc agc agc tac ccc acc ggg atc gcc   318
Gly Lys Arg Glu Leu Arg Leu Ser Ser Ser Tyr Pro Thr Gly Ile Ala
            -50                 -45                 -40

gac ttg aag gcc ggg cct gcc cag act gtc att cgg ccc cag gat gtg   366
Asp Leu Lys Ala Gly Pro Ala Gln Thr Val Ile Arg Pro Gln Asp Val
        -35                 -30                 -25

aag ggc tcc tct cgc agc ccc cag gcc agc att ccg gat gca gcc cgc   414
Lys Gly Ser Ser Arg Ser Pro Gln Ala Ser Ile Pro Asp Ala Ala Arg
    -20                 -15                 -10

atc cga gtc aag cgc tac cgc cag agt atg aac aac ttc cag ggc ctg   462
Ile Arg Val Lys Arg Tyr Arg Gln Ser Met Asn Asn Phe Gln Gly Leu
 -5              -1  1                   5                  10

cgg agc ttc ggc tgt cgc ttt ggg acg tgc acc gtg cag aag ctg gcg   510
Arg Ser Phe Gly Cys Arg Phe Gly Thr Cys Thr Val Gln Lys Leu Ala
             15                  20                  25

cac cag atc tac cag ttc acg gac aaa gac aag gac ggc gtc gcc ccc   558
His Gln Ile Tyr Gln Phe Thr Asp Lys Asp Lys Asp Gly Val Ala Pro
         30                  35                  40

cgg agc aag atc agc ccc cag ggc tac ggc cgc cgg cgc cga cgc tct   606
Arg Ser Lys Ile Ser Pro Gln Gly Tyr Gly Arg Arg Arg Arg Arg Ser
     45                  50                  55

ctg ccc gaa gcc agc ctg ggc cgg act ctg agg tcc cag gag cca cag   654
Leu Pro Glu Ala Ser Leu Gly Arg Thr Leu Arg Ser Gln Glu Pro Gln
 60                  65                  70                  75

gcg cac ggg gcc ccg gcc tcc ccg gcg cat caa gtg ctc gcc act ctc   702
Ala His Gly Ala Pro Ala Ser Pro Ala His Gln Val Leu Ala Thr Leu
```

80 85 90

ttt agg att taggcgccta ctgtggcagc agcgaacagt cgcgcatgca 751
Phe Arg Ile

tcatgccggc gcttcctggg gcgggggggct tcccggagcc gagcccctca gcggctgggg 811

cccgggcaga gacagcattg agagaccgag agtccgggag gcacagacca gcggcgagcc 871

ctgcatttc aggaacccgt cctgcttgga ggcagtgttc tcttcggctt aatccagccc 931

gggtccccgg gtgggggtgg agggtgcaga ggaatccaaa ggagtgtcat ctgccaggct 991

cacggagagg agaaactgcg aagtaaatgc ttagaccccc aggggcaagg gtctgagcca 1051

ctgccgtgcc gcccacaaac tgatttctga aggggaataa ccccaacagg gcgcaagcct 1111

cactattact tgaactttcc aaaacctaga gaggaaaagt gcaatgtatg ttgtatataa 1171

agaggtaact atcaatattt aagtttgttg ctgtcaagat tttttttgt aacttcaaat 1231

atagagatat ttttgtacgt tatatattgt attaagggca ttttaaaaca attgtattgt 1291

tcccctcccc tctattttaa tatgtgaatg tctcagcgag gtgtaacatt gtttgctgcg 1351

cgaaatgtga gagtgtgtgt gtgtgtgtgc gtgaaagaga gtctggatgc ctcttgggga 1411

agaagaaaac accatatctg tataatctat ttacataaaa tgggtgatat gcgaagtagc 1471

aaaccaataa actgtctcaa tg 1493

<210> 4
<211> 188
<212> PRT
<213> Sus scrofa

<400> 4

Met Lys Leu Val Pro Val Ala Leu Met Tyr Leu Gly Ser Leu Ala Phe
-90 -85 -80

Leu Gly Ala Asp Thr Ala Arg Leu Asp Val Ala Ala Glu Phe Arg Lys
-75 -70 -65

Lys Trp Asn Lys Trp Ala Leu Ser Arg Gly Lys Arg Glu Leu Arg Leu
-60 -55 -50

Ser Ser Ser Tyr Pro Thr Gly Ile Ala Asp Leu Lys Ala Gly Pro Ala
-45 -40 -35

Gln Thr Val Ile Arg Pro Gln Asp Val Lys Gly Ser Ser Arg Ser Pro
-30 -25 -20 -15

Gln Ala Ser Ile Pro Asp Ala Ala Arg Ile Arg Val Lys Arg Tyr Arg
-10 -5 -1 1

Gln Ser Met Asn Asn Phe Gln Gly Leu Arg Ser Phe Gly Cys Arg Phe
5 10 15

Gly Thr Cys Thr Val Gln Lys Leu Ala His Gln Ile Tyr Gln Phe Thr
20 25 30

Asp Lys Asp Lys Asp Gly Val Ala Pro Arg Ser Lys Ile Ser Pro Gln
35 40 45 50

Gly Tyr Gly Arg Arg Arg Arg Arg Ser Leu Pro Glu Ala Ser Leu Gly
55 60 65

Arg Thr Leu Arg Ser Gln Glu Pro Gln Ala His Gly Ala Pro Ala Ser
70 75 80

Pro Ala His Gln Val Leu Ala Thr Leu Phe Arg Ile

85 90

<210> 5
<211> 1376
<212> DNA
<213> Rattus norvegicus

<220>
<221> CDS
<222> (154)..(708)

<220>
<221> mat peptide
<222> (433)..(582)

<400> 5
tccagccttt accgctcctg gtttctcggc ttctcatcgc agtcagtctt ggactttgcg 60

ggttttgccg ctgtcagaag gacgtctcgg actttctgct tcaagtgctt gacaactcac 120

cctttcagca gggtatcgga gcatcgctac aga atg aag ctg gtt tcc atc gcc 174
Met Lys Leu Val Ser Ile Ala
-90

ctg atg tta ttg ggt tcg ctc gcc gtt ctc ggc gcg gac acc gca cgg 222
Leu Met Leu Leu Gly Ser Leu Ala Val Leu Gly Ala Asp Thr Ala Arg
-85 -80 -75

ctc gac act tcc tcg cag ttc cga aag aag tgg aat aag tgg gcg cta 270
Leu Asp Thr Ser Ser Gln Phe Arg Lys Lys Trp Asn Lys Trp Ala Leu
-70 -65 -60 -55

agt cgt ggg aag agg gaa cta caa gcg tcc agc agc tac cct acg ggg 318
Ser Arg Gly Lys Arg Glu Leu Gln Ala Ser Ser Ser Tyr Pro Thr Gly
-50 -45 -40

ctc gtt gat gag aag aca gtc ccg acc cag act ctt ggg ctc cag gac 366
Leu Val Asp Glu Lys Thr Val Pro Thr Gln Thr Leu Gly Leu Gln Asp
-35 -30 -25

aag cag agc acg tct agc acc cca caa gcc agc act cag agc aca gcc 414
Lys Gln Ser Thr Ser Ser Thr Pro Gln Ala Ser Thr Gln Ser Thr Ala
-20 -15 -10

cac att cga gtc aaa cgc tac cgc cag agc atg aac cag ggg tcc cgc 462
His Ile Arg Val Lys Arg Tyr Arg Gln Ser Met Asn Gln Gly Ser Arg
-5 -1 1 5 10

agc act gga tgc cgc ttt ggg acc tgc aca atg cag aaa ctg gct cac 510
Ser Thr Gly Cys Arg Phe Gly Thr Cys Thr Met Gln Lys Leu Ala His
15 20 25

cag atc tac cag ttt aca gac aaa gac aag gac ggc atg gcc ccc aga 558
Gln Ile Tyr Gln Phe Thr Asp Lys Asp Lys Asp Gly Met Ala Pro Arg
30 35 40

aac aag atc agc cct caa ggc tat ggc cgc cgg cgc cgg cgt tcc ctg 606
Asn Lys Ile Ser Pro Gln Gly Tyr Gly Arg Arg Arg Arg Arg Ser Leu
45 50 55

cca gag gtc ctc cga gcc cgg act gtg gag tcc tcc cag gag cag aca 654
Pro Glu Val Leu Arg Ala Arg Thr Val Glu Ser Ser Gln Glu Gln Thr
60 65 70

cac tca gct cca gcc tcc ccg gcg cac caa gac atc tcc aga gtc tct 702
His Ser Ala Pro Ala Ser Pro Ala His Gln Asp Ile Ser Arg Val Ser
75 80 85 90

agg tta taggtgcggg tggcagcatt gaacagtcgg gcgagtatcc cattggcgcc 758
Arg Leu

tgcggaatca gagagcttcg caccctgagc ggactgagac aatcttgcag agatctgcct 818

ggctgcccct aggggaggca gaggaaccca agatcaagcc aggctcacgt cagaaaccga 878

gaattacagg ctgatactct ctccgggcag gggtctgagc cactgccttg cccgctcata 938

aactggtttt ctcacggggc atacggctca ttacttactt gaactttcca aaacctagcg 998

aggaaaagtg caatgcttgt tatacagcca aaggtaacta tcatatttaa gtttgttgat 1058

gtcaagaggt ttttttttt gtaacttcaa atatatagaa atatttttgt acgttatata 1118

ttgtattaag ggcattttaa agcgattata ttgtcacctt cccctatttt aagaagtgaa 1178

tgtctcagca aggtgtaagg ttgtttggtt ccgtgtgtgt gtgtgtgtgt gtgtgtgtgt 1238

gtgtgtgtgt gtgtgtgtaa ggtggagagc gcctgattac cgcctgtgga tgaagaaaaa 1298

acattgtgtc ttctataatc tatttacata aaatatgtga tctgggaaaa agcaaaccaa 1358

taaactgtct caatgctg 1376

<210> 6
<211> 185
<212> PRT
<213> Rattus norvegicus

<400> 6

Met Lys Leu Val Ser Ile Ala Leu Met Leu Leu Gly Ser Leu Ala Val
-90 -85 -80

Leu Gly Ala Asp Thr Ala Arg Leu Asp Thr Ser Ser Gln Phe Arg Lys
-75 -70 -65

Lys Trp Asn Lys Trp Ala Leu Ser Arg Gly Lys Arg Glu Leu Gln Ala

-60 -55 -50

Ser Ser Ser Tyr Pro Thr Gly Leu Val Asp Glu Lys Thr Val Pro Thr
-45 -40 -35 -30

Gln Thr Leu Gly Leu Gln Asp Lys Gln Ser Thr Ser Ser Thr Pro Gln
-25 -20 -15

Ala Ser Thr Gln Ser Thr Ala His Ile Arg Val Lys Arg Tyr Arg Gln
-10 -5 -1 1

Ser Met Asn Gln Gly Ser Arg Ser Thr Gly Cys Arg Phe Gly Thr Cys
5 10 15

Thr Met Gln Lys Leu Ala His Gln Ile Tyr Gln Phe Thr Asp Lys Asp
20 25 30 35

Lys Asp Gly Met Ala Pro Arg Asn Lys Ile Ser Pro Gln Gly Tyr Gly
40 45 50

Arg Arg Arg Arg Arg Ser Leu Pro Glu Val Leu Arg Ala Arg Thr Val
55 60 65

Glu Ser Ser Gln Glu Gln Thr His Ser Ala Pro Ala Ser Pro Ala His
70 75 80

Gln Asp Ile Ser Arg Val Ser Arg Leu
85 90

Please type a plus sign (+) inside this box → [X]

PTO/SB/01 (12-97)
Approved for use through 9/30/00. OMB 0651-0032
Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

DECLARATION FOR UTILITY OR DESIGN PATENT APPLICATION (37 CFR 1.63)

[X] Declaration Submitted with Initial Filing OR [ ] Declaration Submitted after Initial Filing (surcharge (37 CFR 1.16 (e)) required)

Attorney Docket Number	YAM 2 0013
First Named Inventor	Toshihiko YANAGITA
COMPLETE IF KNOWN	
Application Number	/
Filing Date	
Group Art Unit	
Examiner Name	

As a below named inventor, I hereby declare that:

My residence, post office address, and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

COMPOSITION FOR PROMOTING PASSIVE EXTENSION OF BLADDER SMOOTH MUSCLE

(Title of the Invention)

the specification of which
[ ] is attached hereto
OR
[X] was filed on (MM/DD/YYYY) 06/23/2000 as United States Application Number or PCT International Application Number PCT/JP00/04166 and was amended on (MM/DD/YYYY) _____ (Article 34) (if applicable).

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment specifically referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1.56.

I hereby claim foreign priority benefits under 35 U.S.C. 119(a)-(d) or 365(b) of any foreign application(s) for patent or inventor's certificate, or 365(a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or of any PCT international application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application Number(s)	Country	Foreign Filing Date (MM/DD/YYYY)	Priority Not Claimed	Certified Copy Attached? YES	Certified Copy Attached? NO
11-177549	JAPAN	06/23/1999	[ ]	[ ]	[X]
			[ ]	[ ]	[ ]
			[ ]	[ ]	[ ]
			[ ]	[ ]	[ ]

[ ] Additional foreign application numbers are listed on a supplemental priority data sheet PTO/SB/02B attached hereto:

I hereby claim the benefit under 35 U.S.C. 119(e) of any United States provisional application(s) listed below.

Application Number(s)	Filing Date (MM/DD/YYYY)

[ ] Additional provisional application numbers are listed on a supplemental priority data sheet PTO/SB/02B attached hereto.

Burden Hour Statement: This form is estimated to take 0.4 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → [X]

PTO/SB/01 (12-97)
Approved for use through 9/30/00. OMB 0651-0032
Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

DECLARATION — Utility or Design Patent Application

I hereby claim the benefit under 35 U.S.C. 120 of any United States application(s), or 365(c) of any PCT international application designating the United States of America, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT international application in the manner provided by the first paragraph of 35 U.S.C. 112, I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.

U.S. Parent Application or PCT Parent Number	Parent Filing Date (MM/DD/YYYY)	Parent Patent Number (If applicable)

☐ Additional U.S. or PCT international application numbers are listed on a supplemental priority data sheet PTO/SB/02B attached hereto.

As a named inventor, I hereby appoint the following registered practitioner(s) to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith: ☐ Customer Number [ ] → Place Customer Number Bar Code Label here

OR

☒ Registered practitioner(s) name/registration number listed below

Name	Registration Number	Name	Registration Number
Richard M. Klein	33,000		

☐ Additional registered practitioner(s) named on supplemental Registered Practitioner Information sheet PTO/SB/02C attached hereto.

Direct all correspondence to: ☐ Customer Number or Bar Code Label [ ] OR ☒ Correspondence address below

Name	Richard M. Klein						
Address	FAY, SHARPE, FAGAN, MINNICH & McKEE, LLP						
Address	1100 Superior Avenue, Seventh Floor						
City	Cleveland			State	OH	ZIP	44114
Country	U.S.A.	Telephone	(216) 861-5582			Fax	(216) 241-1666

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001 and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Name of Sole or First Inventor: ☐ A petition has been filed for this unsigned inventor

Given Name (first and middle [if any])	Family Name or Surname
Toshihiko	YANAGITA

Inventor's Signature	Toshihiko Yanagita					Date	12/10/01
Residence: City	Miyazaki-shi	State	Miyazaki	Country	JAPAN	Citizenship	JAPAN
Post Office Address	5-10 Banbelhouse A-401, 940, Oaza Tsunehisa						
Post Office Address							
City	Miyazaki-shi	State	Miyazaki	ZIP	880-0916	Country	JAPAN

☐ Additional Inventors are being named on the ____ supplemental Additional Inventor(s) sheet(s) PTO/SB/02A attached hereto